- Joined
- Dec 13, 2008
- Messages
- 141
- Reaction score
- 3
Hey guys,
Everyone knows there are massive turf wars when it comes to not only specific procedures (e.g. carotid stenting- cards vs vasc vs neurosurg) but what procedure patients should be offered (e.g. stents vs. CAGS). In terms of the latter example, cardiothoracics has pretty much been squashed because of cardiologists being the 2nd line 'gatekeepers' and thus offering their patients stents before they even get a CTS opinion. CAGS seems relegated to triple vessel disease or left main etc. based on largely outdated data...newer series w arterial grafts, off pump etc show dramatic improvements. People with single vessel disease may benefit from these procedures more than a stent. Still we only see 3xCAGS or up.
What has always struck me as a good solution to the gatekeeper bias is PCPs referring to multidisciplinary teams, where the surgeons and docs can duke it out with data and take into account the anatomy in choosing what to do. It works so well for oncology- for example, limited prostate CA where the data shows equal efficacy between EBRT/seeds/prostatectomy, all cases get discussed and a plan agreed on.
So getting to my question- why don't all patients get put into an MDM meeting between cards and cardiothoracics after their angio? Should cardiologists be allowed to stent then and there- do you think there is improved outcome by this or by waiting 1wk or however many days til the meeting and deciding on what to definitively do? Or do you think this is wasteful (patient is on the table with PCI in and cardiologist doesn't stent, only to stent the next week or whatever).
Interested to hear opinions on whether MDMs could work outside of oncology to diffuse turf wars
Everyone knows there are massive turf wars when it comes to not only specific procedures (e.g. carotid stenting- cards vs vasc vs neurosurg) but what procedure patients should be offered (e.g. stents vs. CAGS). In terms of the latter example, cardiothoracics has pretty much been squashed because of cardiologists being the 2nd line 'gatekeepers' and thus offering their patients stents before they even get a CTS opinion. CAGS seems relegated to triple vessel disease or left main etc. based on largely outdated data...newer series w arterial grafts, off pump etc show dramatic improvements. People with single vessel disease may benefit from these procedures more than a stent. Still we only see 3xCAGS or up.
What has always struck me as a good solution to the gatekeeper bias is PCPs referring to multidisciplinary teams, where the surgeons and docs can duke it out with data and take into account the anatomy in choosing what to do. It works so well for oncology- for example, limited prostate CA where the data shows equal efficacy between EBRT/seeds/prostatectomy, all cases get discussed and a plan agreed on.
So getting to my question- why don't all patients get put into an MDM meeting between cards and cardiothoracics after their angio? Should cardiologists be allowed to stent then and there- do you think there is improved outcome by this or by waiting 1wk or however many days til the meeting and deciding on what to definitively do? Or do you think this is wasteful (patient is on the table with PCI in and cardiologist doesn't stent, only to stent the next week or whatever).
Interested to hear opinions on whether MDMs could work outside of oncology to diffuse turf wars